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Objectives: The aim was to describe treatment patterns and measure real-world
outcomes with tobramycin powder for inhalation (TIPTM), tobramycin inhalation
solution (TIS), and other tobramycin formulations (OTF), using Que´bec’s provincial
public drug reimbursement program database (RAMQ).
Methods: CF patients covered by the RAMQ who had a prescription either of
TIP, TIS, or OTF on at least one occasion during the period from 01.01.2011
to 30.06.2012 were selected. Patient’s characteristics, drug utilization patterns and
resource utilization were analyzed.
Results: Data were available for a sample of 244 eligible patients: 95 on TIP, 130
on TIS and 149 on OTF. The average age of the sample was 24.3 years (SD=12.5),
56.1% were male. Treatment adherence as measured by medication possession ratio
(MPR) and treatment persistence at 6 months were estimated. Higher medication
costs on the TIP group were partially offset by lower healthcare resource utilization
costs associated (Table 1). Annual rate of exacerbations was 0.5 for patients on TIP
and 0.7 for patients on TIS and OTF.
Table 1.
Characteristics Patients on TIP Patients on TIS Patients on OTF
Average MPR [% (SD)] 52.8 (34.5) 41.4 (29.9) 39.7 (33.8)
Proportion of patients (%)
treatment persistent at 6 months
78.4 62.8 56.5
Medication costs [mean (SD)] $4,772 ($3,178) $3,710 ($2,724) $3,406 ($4,245)
Health care resource utilization
costs [mean (SD)]
$831 ($2,195) $1,214 ($2,245) $905 ($1,628)
Conclusions: In a real life setting, TIP was associated with a high level of treatment
adherence (as demonstrated by a high MPR and persistence at 6 months) and
low utilization of additional healthcare resources (such as hospitalisation due to
exacerbations).
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Objectives: Patients with cystic ﬁbrosis (CF) have to maintain a signiﬁcant daily treatment load and
the burden of nebulised therapies remains high. This combined retrospective and prospective obser-
vational study describes the change in patients’ perception of treatment burden, global satisfaction
and convenience following initiation of the TOBI® Podhaler®.
Methods: Patients aged 14 y with chronic Pseudomonas infection were screened and those
completing 1 cycle of TOBI® Podhaler® treatment were recruited to the study. Patients completed
the CFQ-R, Treatment Satisfaction Questionnaire for Medication (TSQM) and modiﬁed TSQM, at
baseline and on completion of cycle 1 and 3 of treatment (at 1 and 5 months). The primary endpoint
of the study was the change in the Treatment Burden domain score of the CFQ-R at 1 and 5 months.
Results: 115 patients were screened from 5 UK CF centres, April 2012 to May 2013, 87 who
completed at least 1 cycle of treatment were included in the study (mean age 29.4 y (SD 8.4),
48 (55%) male). 68/87 (78%) patients completed 3 cycles. At baseline, 54/87 (62%) were taking
2 nebulised therapies. Results of CFQ-R and TSQMs are shown in Table 1.
Conclusion: TOBI® Podhaler® was associated with signiﬁcant improvements in perceived treatment
burden, global satisfaction and convenience at 1 month. Quality of life improvements were sustained
for up to 5 months.
Table 1.
Patient-reported outcome Mean change in score*
measure and domain After 1 cycle of treatment
(1 month)
After 3 cycles of treatment
(5 months)
CFQ-R Treatment burden +7.9 (n = 84) (p< 0.01) +6.5 (n = 55) (p = 0.089)
TSQM Global satisfaction +12.9 (n = 83) (p< 0.001) +19.9 (n = 57) (p< 0.001)
TSQM Convenience +25.6 (n = 83) (p< 0.001) +29.7 (n = 57) (p< 0.001)
TSQM Modiﬁed
(convenience of storage,
assembly and care)
+24.2 (n = 80) (p< 0.001) +27.0 (n = 55) (p< 0.001)
Student t test − against a minimum clinically signiﬁcant difference of 1 standard error
*All scores are out of 100, increased scores are indicative of improvement.
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Objectives: The aim of the study was to compare the efﬁcacy of tobramycin
powder for inhalation (TIP™) relative to tobramycin inhalation solution 300mg/5ml
(TIS-T) and 300mg/4ml (TIS-B), aztreonam lysine inhalation solution (AZLI),
colistimethate sodium (colistin) and colistin inhalation powder (colistin-P) for the
treatment of CF patients with chronic Pa lung infection.
Methods: A systematic literature review was conducted for 2010–2012 to update
a previously conducted NMA (Littlewood 2012). Individual study results were
indirectly compared with a Bayesian NMA. The analysis was performed for change
from baseline in FEV1% predicted at week 4. As some trials included naı¨ve
and previously exposed patients in different arms, these were considered separate
treatment-by-population groups in the analysis.
Results: Three new randomized controlled trials (Assael 2012, Galeva 2012,
Schuster 2012) were identiﬁed in addition to the previous NMA (11 studies). Table 1
shows the difference between TIP and comparators for FEV1% predicted at week 4
for naı¨ve and exposed populations (95% Credible Interval) and the probability (P)
that TIP is better than the comparator. Positive differences in FEV1% predicted and
P> 50% favour TIP.
Conclusion: TIP is highly likely to be favourable in comparison to colistin-P and
results in similar improvements in changes in FEV1% predicted as other licensed
options for CF patients with chronic Pa infection.
Table 1
Change in FEV1% predicted at 4 weeks
TIS-T TIS-B AZLI Colistin-P Colistin
Naı¨ve Exposed Naı¨ve Exposed Naı¨ve Naı¨ve Exposed
TIP −1.97
(−11.84, 8.03)
−0.78
(−7.65, 5.99)
−2.38
(−12.71, 7.98)
0.01
(−10.42, 10.46)
1.53
(−7.04, 10.00)
11.36
(−1.75, 24.31)
−5.75
(−21.23, 9.89)
P 33% 39% 32% 50% 65% 96% 21%
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Background: In children with cystic ﬁbrosis (CF) lung damage secondary to
chronic infection is associated with poorer growth, increased need for antibiotics
and hospitalization, and premature mortality.
Objectives: To determine the efﬁcacy of the inhalation therapy with Colistin in
P. aeruginosa lung infection in children with CF.
Methods: The study includes 14 children with the average age 4.19±1.7 years
(1−3 years − 5 children; 3−6 years − 9 children) with CF who received Colistin
treatment for 6 months. The diagnosis was established according to typical clinical
signs of CF, positive sweat test, genetic testing with determining the CFTR
mutations. In our case, 8 patients were heterozygous and 4 homozygous for F508del.
All the children suffered from P. aeruginosa pulmonary infection.
Results: During inhaled Colistin therapy, a positive dynamic of respiratory syn-
drome’s evolution was observed: decreased cough intensity and frequency, diminish-
ing of the quantity of sputum. Before undergoing Colistin treatment, the colonisation
rate with P. aeruginosa was 108−103. As a result of the inhaled therapy course, after
multiple sputum examination, in 3 children no modiﬁcations of the concentration
of P. aeruginosa in sputum were noticed, in 8 cases it decreased with 1−3 titres,
and in 3 children P. aeruginosa was eradicated. A positive dynamic of the nutrition
status and increasing of BMI from 14.52±2.52 to 15.35±2.76 was also observed
in these children.
Conclusion: Inhaled Colistin therapy allows to accomplish the eradication of
P. aeruginosa infection in infants with CF, to control it in preschool children and
inﬂuences positive the nutrition status of these children.
